The objective of this clinical trial is to compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients. These patients must be candidates for liver transplantation, who have failed seroconversion (anti-HBs \< 10 IU/ml) after three intramuscular doses of 40 µg.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
112
Patients receive a second cycle of vaccination
Patients receive vaccination according to the guidelines.
Virgen del Rocío Hospital
Seville, Spain
Post-vaccination serological response
To compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients potential candidates for liver transplantation, who have failed seroconversion (anti-HBs \< 10 IU/ml) after three intramuscular doses of 40 µg at 0, 1 and 2 months.
Time frame: At 35 ± 5 days after administration
Association of serological response to HBV vaccination to etiology and severity of cirrhosis
Etiology and severity of cirrhosis
Time frame: After 6 months
Association of serological response to HBV vaccination to diabetes presence
Diabetes
Time frame: After 6 months
Association of serological response to HBV vaccination to body mass index
Body mass index
Time frame: At baseline
Association of serological response to HBV vaccination to anti-Hepatitis B core antigen positive presence
Presence of anti-Hepatitis B core antigen positive
Time frame: At baseline
Association of serological response to HBV vaccination to obesity
Obesity
Time frame: After 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.